This week, Mad in America examines four new studies around harms linked to psychiatric drug use. The first finds that ...
The marijuana industry has boomed on the Coast with more than 50 marijuana-related businesses opening since medical marijuana ...
NI research reveals stark breast cancer survival inequalities linked to home values, as a £383,600 study examines patients ...
WELTRUZA™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of ...
A joint European task force of geriatricians and psychiatrists warns that fragmented physical and mental healthcare is ...
The total Bulimia Nervosa market size in the 7MM is expected to grow with significant CAGR during the study period, driven by rising awareness, expanding mental health infrastructure, and growing ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
Weltruza is a long-acting antipsychotic given subcutaneously once a month, in three strengths that correspond to 10, 15, and ...
Italy's Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug's clinical studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results